Stefan Lutz Biography and Net Worth

Chief Scientific Officer of Codexis

Stefan Lutz joined Codexis in 2020 as the Senior Vice President of Research to lead the company’s research team advancing the discovery of proteins. Prior to his arrival in Redwood City, he was a Professor and Chair of the Chemistry Department at Emory University, having joined the university in 2002 and ascending to Chemistry Department Chair in 2014. In addition to his academic work, he has consulted for AgriMetis and served on the scientiﬁc advisory boards of ZuvaChem, CODA Genomics Inc. and SynBioX Inc. Stefan has co-authored more than 65 articles published in peer-reviewed journals and six technical books and journals. He holds six patents and is a frequent lecturer and speaker. Dr. Lutz received a BSc in chemistry/chemical engineering from the Zurich University of Applied Sciences, an MSc in Biotechnology from the University of Teesside and a PhD in chemistry from the University of Florida. He was a postdoctoral fellow at Pennsylvania State University.

What is Stefan Lutz's net worth?: The estimated net worth of Stefan Lutz is at least $288.23 thousand as of February 24th, 2026. Dr. Lutz owns 130,421 shares of Codexis stock worth more than $288,230 as of July 20th. This net worth evaluation does not reflect any other investments that Dr. Lutz may own. Learn More about Stefan Lutz's net worth.
How do I contact Stefan Lutz?: The corporate mailing address for Dr. Lutz and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Stefan Lutz's contact information.
Has Stefan Lutz been buying or selling shares of Codexis?: Stefan Lutz has not been actively trading shares of Codexis in the last ninety days. Most recently, Stefan Lutz sold 5,862 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $1.13, for a transaction totalling $6,624.06. Following the completion of the sale, the insider now directly owns 130,421 shares of the company's stock, valued at $147,375.73. Learn More on Stefan Lutz's trading history.
Who are Codexis' active insiders?: Codexis' insider roster includes Raymond De Vré (Director), Byron Dorgan (Director), Georgia Erbez (Chief Financial Officer and Chief Business Officer), Bernard Kelley (Director), Stefan Lutz (Chief Scientific Officer), Alison Moore (President and CEO), John Nicols (CEO), Kevin Norrett (COO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.
Are insiders buying or selling shares of Codexis?: In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 35,774 shares worth more than $65,308.44. The most recent insider tranaction occured on June, 11th when Director Vre Raymond De sold 2,605 shares worth more than $6,173.85. Insiders at Codexis own 3.5% of the company. Learn More about insider trades at Codexis.
Information on this page was last updated on 6/11/2026.

Stefan Lutz Insider Trading History at Codexis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/24/2026	Sell	5,862	$1.13	$6,624.06	130,421
2/6/2026	Sell	2,492	$1.31	$3,264.52	136,283
1/7/2026	Sell	4,685	$1.70	$7,964.50	138,775

Stefan Lutz Buying and Selling Activity at Codexis

Codexis Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Today's Range

Now: $2.21

$2.14

$2.27

50 Day Range

MA: $2.48

$2.13

$2.80

2 Week Range

Now: $2.21

$0.96

$3.87

Volume

506,418 shs

Average Volume

812,612 shs

Market Capitalization

$200.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.5